Lakefront Biotherapeutics
Lakefront Biotherapeutics is an American clinical-stage biotechnology company focused on the discovery and development of novel biological cancer therapeutics. The company concentrates its scientific research on engineering targeted immuno-oncology therapies and specialized biological molecules to treat complex solid tumors. Its drug development pipeline features proprietary monoclonal antibodies and recombinant proteins designed to enhance anti-tumor immune responses. Primary revenue is derived from biopharmaceutical research collaborations, licensing agreements, and upfront milestone payments from development partners. Lakefront Biotherapeutics holds an established position as a specialized oncology drug discovery enterprise. The company is headquartered in the United States.
9 of the funds FundTelligence covers report a position in Lakefront Biotherapeutics.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 9
Funds holding Lakefront Biotherapeutics
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Europa Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)
- SPP Generation 50-tal — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- SPP Generation 40-tal — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Global All Countries — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 9 funds holding it.